Efficacy of etrasimod on symptomatic relief in patients with ulcerative colitis: an analysis of the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials

被引：0

作者：

Chaparro, M. ^{[1
]}

Armuzzi, A. ^{[2
]}

Irving, P. M. ^{[3
,4
]}

Allez, M. ^{[5
]}

Dubinsky, M. C. ^{[6
]}

Sands, B. E. ^{[7
]}

Goetsch, M. ^{[8
]}

Wang, W. ^{[9
]}

Shan, K. ^{[10
]}

Woolcott, J. ^{[11
]}

Bartolome, L. ^{[12
]}

Wosik, K. ^{[13
]}

Panaccione, R. ^{[14
]}

机构：

[1] Univ Autonoma Madrid, Hospital Univ Princesa, Inst Invest Sanitaria Princesa IIS Princesa,Gastr, Centro Invest Biomed Red Enfermedades Hepat & Dig, Madrid, Spain

[2] IRCCS Humanitas Res Hosp Rozzano, IBD Ctr, Milan, Italy

[3] Guys & St Thomas NHS Fdn Trust, Gastroenterol, London, England

[4] Kings Coll London, Sch Immunol Microbial Sci, London, England

[5] Univ Paris, Gastroenterol, Hop St Louis, Diderot, France

[6] Icahn Sch Med Mt Sinai, Feinstein IBD Ctr, New York, NY USA

[7] Icahn Sch Med Mt Sinai, Dr Henry Janowitz Div Gastroenterol, New York, NY USA

[8] Pfizer AG, Global Clin Dev, Zurich, Switzerland

[9] Pfizer Inc, Biostat, Collegeville, PA USA

[10] Pfizer Inc, Biostat, New York, NY USA

[11] Pfizer Inc, Global Med Affairs Gastroenterol, Collegeville, PA USA

[12] Pfizer Inc, Global Hlth Econ & Outcomes Res Inflammat &, New York, NY USA

[13] Pfizer Inc, Global Med Affairs Gastroenterol, Kirkland, PQ, Canada

[14] Univ Calgary, Inflammatory Bowel Dis Unit, Div Gastroenterol & Hepatol, Calgary, AB, Canada

来源：

JOURNAL OF CROHNS & COLITIS | 2023年 / 17卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

DOP42

引用

页码：I107 / I110

页数：5

共 50 条

[1] EFFICACY OF ETRASIMOD ON SYMPTOMATIC RELIEF IN PATIENTS WITH ULCERATIVE COLITIS: AN ANALYSIS OF THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS
Chaparro, Maria
Armuzzi, Alessandro
Irving, Peter M.
Allez, Matthieu
Dubinsky, Marla C.
Sands, Bruce E.
Goetsch, Martina
Wang, Wenjin
Shan, Kevin
Woolcott, John
Bartolome, Lauren
Wosik, Karolina
Panaccione, Remo
GASTROENTEROLOGY, 2023, 164 (06) : S1099 - S1100
[2] ETRASIMOD FOR THE TREATMENT OF ULCERATIVE COLITIS: ANALYSIS OF INFECTION RATES FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 CLINICAL TRIALS
Regueiro, Miguel D.
Siegmund, Britta
Yarur, Andres J.
Steinwurz, Flavio
Gecse, Krisztina
Goetsch, Martina
Bhattacharjee, Abhishek
Wu, Joseph
Green, Jesse
McDonnell, Aoibhinn
Crosby, Catherine
Lazin, Krisztina
Branquinho, Diogo
Modesto, Irene
Abreu, Maria T.
GASTROENTEROLOGY, 2023, 164 (06) : S1105 - S1106
[3] Etrasimod for the treatment of ulcerative colitis: analysis of infection rates from the phase 3 ELEVATE UC 52 and ELEVATE UC 12 clinical trials
Regueiro, M.
Siegmund, B.
Yarur, A.
Steinwurz, F.
Gecse, K. B.
Goetsch, M.
Bhattacharjee, A.
Wu, J.
Green, J.
McDonnell, A.
Crosby, C.
Lazin, K.
Branquinho, D. Ferreira
Modesto, I.
Abreu, M. T.
JOURNAL OF CROHNS & COLITIS, 2023, 17 : 689 - 690
[4] Efficacy and Safety of Etrasimod in Patients with Ulcerative Colitis in Japan: Data from the Phase 3 ELEVATE UC 12 and ELEVATE UC 40 JAPAN Trials
Takeuchi, Ken
Hisamatsu, Tadakazu
Nakase, Hiroshi
Matsuoka, Katsuyoshi
Keating, Michael
Yuasa, Hirotoshi
Oe, Motoki
Arai, Shoko
Mazur, Rafal
Hibi, Toshifumi
DIGESTION, 2024,
[5] Characterization of plasma inflammatory protein abundance in patients with ulcerative colitis treated with etrasimod: an exploratory analysis of the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials
Siegmund, B.
Ryan, R.
Abreu, M. T.
Vermeire, S.
Dotan, I.
Goetsch, M.
Crosby, C.
Woolcott, J.
Komori, H. K.
Danese, S.
JOURNAL OF CROHNS & COLITIS, 2023, 17 : 700 - 700
[6] CHARACTERIZATION OF PLASMA INFLAMMATORY PROTEIN ABUNDANCE IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH ETRASIMOD: AN EXPLORATORY ANALYSIS OF THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS
Siegmund, Britta
Ryan, Rathi D.
Abreu, Maria T.
Vermeire, Severine
Dotan, Iris
Goetsch, Martina
Crosby, Catherine
Woolcott, John
Komori, H. Kiyomi
Danese, Silvio
GASTROENTEROLOGY, 2023, 164 (06) : S659 - S659
[7] Efficacy and Safety of Etrasimod in Patients With and Without Concomitant Corticosteroid Treatment in the Phase 3 ELEVATE UC 52 and ELEVATE UC 12 Trials
Sands, Bruce E.
Gecse, Krisztina B.
Rubin, David T.
Leung, Yvette
Panes, Julian
Goetsch, Martina
Wang, Wenjin
Shan, Kevin
Woolcott, John C.
Smith, Christina C.
Wosik, Karolina
Schreiber, Stefan
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S808 - S809
[8] Effect of Etrasimod on Circulating Lymphocytes in Patients With Moderately to Severely Active Ulcerative Colitis: Data From the Phase 3 ELEVATE UC 52 and ELEVATE UC 12 Trials
Danese, Silvio
Komori, H. Kiyomi
Ryan, Rathi D.
Cataldi, Fabio
Lee, Caroline A.
Goetsch, Martina
Siegmund, Britta
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S673 - S673
[9] Non-serious adverse events in patients with ulcerative colitis receiving etrasimod: An analysis of the phase 2 OASIS and phase 3 ELEVATE UC 52 and ELEVATE UC 12 clinical trials
Lees, C.
Torres, J.
Leung, Y.
Vermeire, S.
Fellmann, M.
Modesto, I.
McDonnell, A.
Lazin, K.
Keating, M.
Goetsch, M.
Wu, J.
Loftus, E. V., Jr.
JOURNAL OF CROHNS & COLITIS, 2024, 18 : I1055 - I1057
[10] Effect of etrasimod on immune cell subsets in colonic tissue of patients with ulcerative colitis: immunophenotyping analysis of colon biopsy samples from the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trials
Siegmund, B.
Komori, H. K.
Abreu, M. T.
Vermeire, S.
Dotan, I.
Goetsch, M.
Crosby, C.
Ryan, R.
Woolcott, J.
Danese, S.
JOURNAL OF CROHNS & COLITIS, 2023, 17 : 701 - 703

← 1 2 3 4 5 →